A neck implant designed to treat rheumatoid arthritis provides automatic therapy that lasts one minute per day.
Ivarmacitinib, a novel Janus kinase 1 inhibitor, alleviates symptoms, reduces disease activity, and improves physical function and quality of life in patients with moderate to severe rheumatoid ...
Northwell Health was one of many who conducted a pioneering clinical trial to treat rheumatoid arthritis through a chip implanted on the vagus nerve. The first technology of its kind yielded ...
The Food and Drug Administration has approved a vagus nerve bioimplant to treat rheumatoid arthritis (RA). The scientific foundation of the device is based on decades of research by Dr. Kevin Tracey, ...
WAYNE, Pa., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory diseases, ...
The Nature Index 2024 Research Leaders — previously known as Annual Tables — reveal the leading institutions and countries/territories in the natural and health sciences, according to their output in ...
GlobalData on MSN
FDA approves AbbVie’s Rinvoq for inflammatory bowel disease
The US Food and Drug Administration (FDA) has approved AbbVie’s supplemental new drug application, updating the indication ...
AnaptysBio, Inc. announced they will host an investor call and live webcast on June 3, 2025, to share updated data from their Phase 2b RENOIR clinical trial, which is evaluating the investigational ...
Stocktwits on MSN
AbbVie Stock Rises After FDA Approves Changed Recommendations For Use Of Popular Rinvoq Drug
AbbVie (ABBV) on Monday said that the U.S. Food and Drug Administration has approved an update to the indication statement for its drug Rinvoq for the treatment of adults with moderately to severely ...
Questions remain on whether there are links between patients with asthma and RA, including heterogeneity of disease.
AnaptysBio, Inc., a biotechnology company focused on immunology therapeutics, will hold an investor call and webcast on February 12, 2025, at 8:30 AM ET to discuss top-line results from its Phase 2b ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results